Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)

Komajda, Michel and Lutiger, Beatrix and Madeira, Hugo and Thygesen, Kristian and Bobbio, Marco and Hildebrandt, Per and Jaarsma, Wybren and Riegger, Guenter and Ryden, Lars and Scherhag, Armin and Soler-Soler, Jordi and Remme, Willem J. (2004) Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). EUROPEAN JOURNAL OF HEART FAILURE, 6 (4). pp. 467-475. ISSN 1388-9842, 1879-0844

Full text not available from this repository. (Request a copy)

Abstract

Background: Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits. Aims: CARMEN offered a possibility to study safety and tolerability of enalapril against carvedilol and their combination. Methods: Five hundred and seventy-two patients were blindly up-titrated on carvedilol (target 25 mg bid) and/or enalapril (target 10 mg bid), and continued for 18 months. In the combination arm, carvedilol was up-titrated before enalapril. Results: There was no group related difference in adverse events during up-titration. Withdrawal rates were 31, 30 and 30%, and serious adverse events 28, 29 and 34% in the combination, carvedilol and enalapril arms. Mortality was similar in all groups (all-cause N = 14, 14 and 14; cardiovascular N = 9, 13 and 14). All-cause and cardiovascular hospitalizations occurred in 26, 27 and 32%, and in 12, 16 and 22% in the combination, carvedilol and enalapril arms, respectively. Conclusion: The safety profile was similar in all treatment arms. In contrast to common perception, there was no difference in tolerability between the ACE-I and carvedilol. This result is even more remarkable as the high prestudy use of ACE-I (65%) might have introduced a bias by selecting ACE-I tolerant patients, who were only switched from their former ACE-I to enalapril. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Item Type: Article
Uncontrolled Keywords: RANDOMIZED INTERVENTION TRIAL; MYOCARDIAL-INFARCTION; MERIT-HF; METOPROLOL; SURVIVAL; COPERNICUS; MANAGEMENT; GUIDELINES; DIAGNOSIS; MORBIDITY; carvedilol; enalapril; heart failure; tolerability; CARMEN
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin II
Depositing User: Dr. Gernot Deinzer
Date Deposited: 14 Jul 2021 07:15
Last Modified: 14 Jul 2021 07:15
URI: https://pred.uni-regensburg.de/id/eprint/37574

Actions (login required)

View Item View Item